Company chart and information is provided by TradingView based on 15-minute-delayed data.
Orphazyme AS is a late-stage biopharmaceutical company harnessing the amplification of Heat Shock Proteins. It is engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for four severe orphan diseases: Niemann-Pick disease Type C (NPC), Gaucher disease, Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).
| Website: | www.orphazyme.com |
| Email: | afv@orphazyme.com |
| Main Phone: | +45 28989055 |
| Address: | Ole Maaloes Vej 3 |
| City / Town: | Copenhagen |
| Country: | DK |
| Postal Code: | DK-2200 |
| Exchange: | OTO |
| CEO: | Anders Vadsholt |
| Employees: | 141 |
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
